Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 6Terminated 2Recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Sarcoma 5Genitourinary 3Tumor-Agnostic 2Plasma cell 2NET 2Lymphoid 2Endocrine 2Thoracic 1Other solid neoplasm 1CNS 1

Conditions

Neuroendocrine Tumors 1Metastatic Digestive System Neuroendocrine Tumor G1 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoid Tumor 1Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 15Magnetic Resonance Spectroscopy 9Everolimus 8gallium Ga 68 dotatate 6lanreotide 4cabozantinib 4Temozolomide 4Specimen Handling 4Nivolumab 4Lutetium-177 4Lutetium 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4surufatinib 3olaparib 3copper dotatate CU-64 3Somatostatin 3Injections 3Ga(III)-DOTATOC 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Capecitabine 3pembrolizumab 2fludarabine phosphate 2fludarabine 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Sunitinib 2Radiosurgery 2Octreotide 2Drug Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Sunitinib × NET × Clear all
NCT05773274 2026-05-26

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡